Between Dec. 23, 2024 and Jan. 3, 2025, eCommons staff will not be available to answer email and will not be able to provide DOIs until after Jan. 6. If you need a DOI for a dataset during this period, consider Dryad or OpenICPSR. If you need support submitting material before the winter break, please contact us by Thursday, Dec. 19 at noon. Thank you!
Library

eCommons

 

Diffusion and Binding of Radio-Labeled Antibodies in a Tumor

Simple item page
dc.contributor.authorSchweitzer, Andrew
dc.contributor.authorSu, Wan-Lin
dc.contributor.authorBenlifer, Adam
dc.contributor.authorMathrani, Vikram
dc.contributor.authorAarismaa, Linda
dc.date.accessioned2004-07-13T14:18:01Z
dc.date.available2004-07-13T14:18:01Z
dc.date.issued2004-07-13T14:18:01Z
dc.description.abstractWith the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly emerged as one of the more promising methods of treating cancer cells. RIT makes use of radio-labeled monoclonal antibodies to detect and deliver controlled doses of radiation to malignant cells. The primary advantage of this method is that damage to normal, healthy tissue is minimized. We investigated the use of radio-labeled antibodies as a method of tumor destruction. Our primary interests were the rate of antibody diffusion into the tumor, the antibody binding kinetics, and the overall effectiveness of radioimmunotherapy given the rate of radioactive decay. By modeling the concentration of bound antibody with respect to time, we were able to optimize tumor destruction while minimizing the damage to the surrounding tissue. Our results show that a computer simulation using FIDAP is a time-saving, cost-effective method of obtaining quantitative results about the binding kinetics of antibody to tumor. In addition, we determined that while the binding specificity plays an important role in ensuring proper binding to the tumor, the rate of antibody to antigen complex formation does not affect the treatment and that this process is limited by diffusion. Given this fact, we recommend that low molecular weight antibodies be used because they will typically have higher diffusivities. In an example case of metastatic melanoma, we found that 4.33 mg of 188Re-6D2 complex would destroy the tumor in our model.en_US
dc.format.extent1755251 bytes
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/1813/148
dc.language.isoen_US
dc.relation.ispartofseries2004;10
dc.subjectdrug delivery, tumoren_US
dc.subjecten_US
dc.titleDiffusion and Binding of Radio-Labeled Antibodies in a Tumoren_US
dc.typereporten_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
antibodies.pdf
Size:
1.67 MB
Format:
Adobe Portable Document Format
Download

Collections

BEE 4530 - 2004 Student Papers